Jereme M. Sylvain, Executive Vice President and Chief Financial Officer of Dexcom Inc (NASDAQ:DXCM), filed a Form 4 on August 25, 2026, disclosing a transaction in company common stock dated August 22, 2026.

Key Highlights

  • Reporting person: Jereme M. Sylvain, EVP and Chief Financial Officer of Dexcom Inc.
  • Transaction: 1,451 shares of common stock were disposed of (transaction code F) on August 22, 2026, at a price of $92.34 per share.
  • Purpose of disposal: Shares were withheld by the issuer to cover tax withholding and remittance obligations in connection with the net settlement of restricted stock units, and do not represent a sale by the reporting person, according to the filing.
  • Beneficial ownership following transaction: 150,390 shares of common stock held directly.
  • Unvested RSUs included: 87,094 unvested restricted stock units are included in the post-transaction beneficial ownership figure, according to the filing.

Dexcom CFO's RSU Tax Withholding Transaction and Beneficial Ownership Details

According to the filing, Jereme M. Sylvain, identified as EVP and Chief Financial Officer of Dexcom Inc, reported the disposition of 1,451 shares of common stock on August 22, 2026. The filing states the transaction code is F, and the per-share price was $92.34. The filing's explanation of responses notes that the shares represent the number "required to be withheld by the Issuer to cover tax withholding and remittance obligations in connection with the net settlement of restricted stock units and does not represent a sale by the Reporting Person."

Following the reported transaction, the filing discloses that Sylvain directly beneficially owns 150,390 shares of common stock. The filing specifies that this total includes 87,094 unvested restricted stock units. Of those unvested units, the filing details: 48,774 were granted on March 8, 2026, and shall vest through March 8, 2029; 23,937 were granted on March 8, 2025, and shall vest through March 8, 2028; 5,699 were granted on March 8, 2025, and shall vest through March 8, 2027; and 8,684 were granted on March 8, 2024, and shall vest through March 8, 2027.

No derivative securities transactions were reported in Table II of the filing. The form was signed by Jereme M. Sylvain and dated August 25, 2026.

What Was Disclosed

The filing disclosed a tax-related share withholding of 1,451 Dexcom common shares at $92.34 per share by CFO Jereme M. Sylvain on August 22, 2026, resulting in directly held beneficial ownership of 150,390 shares, including 87,094 unvested restricted stock units.